Financial Data and Key Metrics Changes - Total company revenue for Q4 2021 was $1.56 billion, a 6.8% increase compared to the same quarter in the prior year. For the full year, total revenue increased 12.2% to $6.2 billion compared to $5.5 billion in the prior year [11] - Adjusted EBITDA for Q4 was $138.4 million, down from $221.3 million in the same quarter prior year, with an adjusted EBITDA margin of 8.9% compared to 15.2% [20][36] - Earnings per fully diluted share were $0.37 in Q4, down from $0.57 in the same quarter prior year, while for the full year, earnings per share were $2.98 compared to $1.93 in the prior year [28][41] Business Segment Data and Key Metrics Changes - Revenue in the Critical Illness Recovery Hospitals segment for Q4 increased 7.3% to $577 million, with patient days up 3.2% and net revenue per patient day increasing 3.5% to $1,946 [11][12] - Revenue in the Rehabilitation Hospital segment for Q4 increased 10.5% to $216 million, with patient days up 8.1% and net revenue per patient day increasing 2.7% to $1,888 [14] - Revenue in the Outpatient Rehab segment for Q4 increased 7.8% to $277 million, with patient visits up 9.2% [16] - Revenue in the Concentra segment for Q4 increased 3% to $411 million, with patient visits up 8.3% [18] Market Data and Key Metrics Changes - The company experienced substantial wage pressure in Q4, particularly in critical illness recovery hospitals, with agency nursing rates nearly doubling [6][30] - Patient days in the Critical Illness Recovery Hospitals segment were up 1.9% for the full year, while revenue per patient day increased 6.1% [13] Company Strategy and Development Direction - The company aims to continue admitting critically complex patients despite increased labor costs, leveraging strong referral relationships developed during the pandemic [31] - The company plans to maintain a capital expenditure range of $180 million to $200 million for 2022, primarily focused on maintenance [49][59] Management Comments on Operating Environment and Future Outlook - Management expressed concerns about macroeconomic labor market issues affecting guidance, particularly in the critical illness recovery hospitals segment [53] - The company expects revenue for 2022 to be in the range of $6.25 billion to $6.4 billion, reaffirming a 3-year compound annual growth rate target for revenue of 4% to 6% from 2021 to 2023 [49] Other Important Information - The company recorded $8 million in other operating income in Q4 related to Provider Relief Fund grant payments, compared to $36 million in the same quarter of the prior year [8] - The company ended the year with $3.6 billion of debt outstanding and $74 million of cash on the balance sheet [42] Q&A Session Summary Question: Can you talk about the philosophy behind the withdrawal of guidance? - Management indicated that the guidance was based on strong revenue visibility but was cautious due to macroeconomic labor market issues affecting costs [52][54] Question: Are labor issues isolated to critical illness recovery hospitals? - Labor cost issues are predominantly in critical illness recovery hospitals, with some impact noted in rehabilitation and outpatient rehab segments due to COVID-related staffing challenges [57][58] Question: What are the capital expenditure plans for 2022? - The majority of capital expenditures will be maintenance-related, with a range of $180 million to $200 million anticipated [59] Question: How do you view the testing and screening outlook for 2022? - Management anticipates a decrease in revenue from screening and testing as COVID wanes, but expects overall revenue growth for Concentra [100]

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbers: 001-34465 SELECT MEDICAL HOLDINGS C ...

Select Medical Holdings Corp (NYSE:SEM) Q3 2021 Earnings Conference Call November 4, 2021 9:00 AM ET Company Participants Robert Ortenzio - Co-Founder & Executive Chairman Martin Jackson - EVP & CFO Conference Call Participants Justin Bowers - Deutsche Bank Frank Morgan - RBC Capital Markets Courtney Fondufe - Bank of America Merrill Lynch William Sutherland - The Benchmark Company A.J. Rice - Crédit Suisse Operator Good morning, and thank you for joining us today for Select Medical Holdings Corporation's e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbers: 001-34465 SELECT MEDICAL HOLDINGS CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 20-1764048 (Stat ...

Select Medical Holdings Corporation (NYSE:SEM) Q2 2021 Earnings Conference Call August 6, 2021 9:30 AM ET Company Participants Robert Ortenzio - Executive Chairman and Co-Founder Martin Jackson - Executive Vice President & Chief Financial Officer Conference Call Participants Frank Morgan - RBC Capital Markets Justin Bowers - Deutsche Bank Courtney Fondufe - Bank of America Bill Sutherland - Benchmark Company Operator Good morning, and thank you for joining us today for the Select Medical Holdings Corporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbers: 001-34465 SELECT MEDICAL HOLDINGS CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 20-1764048 (State or ...

Select Medical Holdings Corporation (NYSE:SEM) Q1 2021 Earnings Conference Call May 7, 2021 9:00 AM ET Company Participants Robert Ortenzio - Co-Founder & Executive Chairman Martin Jackson - Executive VP & CFO Conference Call Participants Justin Bowers - Deutsche Bank Frank Morgan - RBC Capital Markets Bill Sutherland - Benchmark Operator Good morning, and thank you for joining us today for the Select Medical Holdings Corporation earnings conference call to discuss the first quarter 2021 results and the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file numbers: 001-34465 SELECT MEDICAL HOLDINGS CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 20-1764048 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 4714 Gettysburg Road, P.O. Box 2034 Mechanicsburg, PA 17055 (Address of Principa ...

Select Medical Holdings Corporation (NYSE:SEM) Q4 2020 Earnings Conference Call February 26, 2021 9:00 AM ET Company Participants Robert Ortenzio - Executive Chairman and Co-Founder Martin Jackson - Executive Vice President and Chief Financial Officer Conference Call Participants Justin Bowers - Deutsche Bank Frank Morgan - RBC Capital Markets Kevin Fischbeck - Bank of America Bill Sutherland - The Benchmark Company AJ Rice - Credit Suisse Operator Good morning and thank you for joining us today for Select ...

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbers: 001-34465 SELECT MEDICAL HOLDINGS C ...